Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good afternoon and welcome to the Orion Q3 2026 conference call and webcast. My name is Tuukka Hirvonen and I am the Head of Investor Relations here at Orion. I am here today with our CEO, Liisa Hurme, and CFO, René Lindell. We will start shortly with Liisa's presentation, after which you will have the possibility to ask questions of the management. We will first take questions from the conference call lines, and afterwards we will turn to the webcast chat questions. So you may type in your questions utilizing the webcast chat function. Before going through the disclaimer for our Finnish-speaking viewers, a CEO interview in Finnish will be published later today on Orion's website regarding the results. And now, before letting Liisa start, a quick reminder about the disclaimer and forward-looking statements. And with this, it is my pleasure to hand over to Liisa.
Thank you, and welcome to the Orion Q3 2026 webcast. Once again, we have delivered a strong quarter with improved sales and profitability growth. Nubeqa continued to be the growth driver, but all business units across our branded products also showed healthy growth. We are proud to share that we have proceeded with our first biological molecule into Phase I, and this is a very important milestone for Orion R&D. Another very important piece of information on the R&D side is our progress. The interim results of the DASL-HiCaP study demonstrated a 58% reduction of the risk of metastasis or death with darolutamide and androgen deprivation therapy and radiotherapy versus a placebo and androgen deprivation therapy and radiotherapy. And this week, after the quarter, we also on Monday announced changes to the Orion Executive Team to continue proceeding with our strategy. And now, let us turn to the numbers. Our net sales increased by 28%, totaling 542 million euros, and our operating profit had a growth of almost 74% and totaled 210 million euros. And our earnings per share grew accordingly. And when we look at the net sales, we clearly see that Innovative Medicines, with Nubeqa, drives our net sales growth with 130 million here. And branded products, of course, with smaller numbers, but a significant growth in branded products of 7.4 million. And this quarter, generics had a bit of a tough time, down 4.6 million. But we have had a very tough comparative period from last year. Animal health was more or less on par. And Fermion reported excellent deliveries to our customers. Regarding our operating profit. Even more clearly, royalties are driving this with 104 million. And maybe the other figure that I would like to point out here are our fixed costs of 22.3 million, which is exactly as we expected it to be. We have been communicating and executing our R&D pipeline projects simultaneously, so all our R&D projects are proceeding. Thus, this results in higher fixed costs. And they are also partly due to the increased sales and marketing costs. Changes in sales volume were also very positive at 4.9 million, and changes in prices, COGS, and product mix contributed 2.6 million, all on the positive side. And now turning to year-to-date numbers from January to September, we see very similar figures, with 24% growth totaling 1 billion and almost 66% growth in operating profit, a bit over 500 million during the first nine months, and again, earnings per share following that growth. And now I turn to separate divisions where we can look at the quarter and also the year-to-date numbers. And here in the dark blue you can see Nubeqa royalties and product sales, 280 million in the third quarter, and then some other services and sales in the lighter blue here. And during the first nine months, net sales reached 662 million. Once again, I would like to point out that on the right side, you can see how the dynamics evolve during the year, as we always start from a lower level of royalty in the first quarter of every year. It is good to remind you here that we reached the highest royalty rate in the second quarter. So the growth that we are seeing here with Nubeqa is an absolute growth of royalties, meaning absolute growth of sales at market. And we had royalties of 222 million and tablet sales of 58 million to Bayer during the Q3. And a very healthy growth for branded products during Q3, almost 11% growth with a portfolio of Easyhaler products where budesonide-formoterol is clearly the growth driver. Our CNS portfolio shows growth there as well. This time, not entacopone growth, but rather growth of some of our new CNS products that we have discussed here earlier. For example, for migraine and some additional products for Parkinson's disease patients. And the fastest growth segment was again Women's Health. The same trend can be seen in the first nine months' figures. Generics and consumer health had, as I said already in the beginning, a quite rough starting point. A quite rough starting point. Comparative period from last year. So quarter three figures are down 3.4%. But still, I think it is a very healthy business here. And when you then look at year-to-date numbers, I think you can say it is on par. We are on the same level as last year, and this is due to the slight decline in the generic prescription drugs. However, the consumer health business is proceeding as it did last year. No decrease has been seen there. And I am happy to report that we have signed a license agreement with the Chinese company Qilu to commercialize IV pembrolizumab, which is a biosimilar of Keytruda across Europe. And the expected launch of this product would be in the early 2030s. Animal health is more or less on par. During Q3 compared to the previous year, we see slightly lower figures in the year-to-date numbers. And Fermion. Great numbers. I already mentioned this at the beginning. And let's remember this is really external deliveries. And this is mainly coming from contract manufacturing and, actually, contract development and manufacturing services for both API and finished dosage forms. So when we report Fermion sales, it includes also contract manufacturing and development for finished drugs. I am happy to report that we are ramping up, as we speak, the plant three in Hanko. That was the plant where we had the water damage in early July. And now we are ahead of schedule and clearly and solidly ramping up that plant, and all the other plants have already been ramped up after the maintenance break as planned. Our top ten products. I believe the order remains the same as last time. And you can see the almost 70% growth for Nubeqa, almost 7% growth for Easyhaler, and a slight decline for Entacapone. This is due to price pressure almost all over the world. It is a global product and we see price decreases in different parts of the globe. Volumes, however, keep on growing all the time. And for the Divina series, you can see almost 47% growth. And I think this is amazing. It is great news for women globally that these treatments are available. And when you look at the animal health numbers, I think part of the explanation is here. It is about the timing of shipments; the sedative shipments again have been a bit later than we expected. It might be just a one-day difference between quarters. So here we see a negative number. And I think the main message on this slide is that almost half of Orion's revenue comes from innovative medicines after the first nine months, meaning Nubeqa royalties and product sales. The clinical development pipeline DASL-HiCaP interim results were reported by Bayer at ESMO. Very positive results, as I already mentioned. And we are also happy to report on the new molecule ODM-216. That is our first biological molecule, a large molecule in our pipeline. And we have a study called BiCIDES going on with this bispecific antibody. And it is targeted to advanced solid tumors. I cannot and will not share any more about specific indications at this stage. Sustainability is an important priority for us. It is not only an item on our agenda that we need to do. We perform every day to take good care of our value chain, from sourcing the starting materials and intermediates, sourcing APIs, sourcing drugs from other companies, to distributing and selling the drugs to our customers. All this is very important. You can see that reflected in the four pillars of our sustainability agenda. And of course, how we are seen by the external environment validates that we are doing well. And I think the recent news is that we have now achieved the silver level by EcoVadis. And of course, we continue the good work and aim even higher. Based on a strong first nine months, very good royalties, and a positive outlook for the rest of the year. We upgraded our financial outlook for this year so that our net sales range is from 2,070 million to 2,140 million. Our range for operating profit is from 730 million to 790 million. And then after the third quarter, as I mentioned earlier this week, we announced changes in our executive team and in our divisional structures. We have not changed our strategy. On the contrary, our strategy has become a necessity. In the beginning, when we launched the strategy in 2023, it was an aspiration for Orion to become a more global company from a European-based pharmaceutical company, to go out to the world both commercially and by building R&D capabilities around the world where they are needed and where they are available. And we have more or less accomplished this. The first three years, we've strengthened our presence in Europe with all our key brands, and we continue to do that. We have established our sales operations in Japan, which actually also serves as a platform for our clinical studies, for example, for ODM-216. So now for the first time, we are running our own studies outside Europe. But now we are moving to the next stage of this strategy. And that means that we need to sharpen up and focus even more on our strategic assets. And thus, we have made some changes in our organization. We have created a new role, a Commercial Executive Vice President for International Commercial Operations, for Mr. Hao Pan is leading this organization. He has been a member of the Orion Executive Team since early 2023. And now he is responsible for all ex-U.S. Commercial operations, as all the US operations are reporting and are headed by Berkeley Vincent. He is also responsible for the Innovative Medicines. The other change is thatMr. Juhani Kankaanpää, who has been heading our global operations, which means all our manufacturing sites, sites for finished goods for APIs, company procurement, and supply chain, also now heads our Generics and Consumer Health division. And we also welcome a new member to our executive team, Mr. Henri Salokangas, as an Executive Vice President for Branded Products, continues in that role. But we have added a hospital business to the respiratory, women's health, and CNS businesses. And why do we do this? I think it underlines the fact that we are becoming more global. We definitely focus on our key brands in branded products. We are building our Europe-wide hospital business. We have the existing products there. Simdax. Dexdor. Some biosimilars that we are already selling across Europe. As I already mentioned, we have made another agreement for new biosimilars. We have made several of those. And we also have value-added hospital products like recombinant albumin under development by our suppliers. So we are building that business unit under the branded division. Then again, the generics business is really about supply, price, and service level. And thus, it is now combined with our global operations, where the bigger picture of that part can be taken care of. And then, a very long-term member of the Orion Executive Team, Mrs. Satu Ahomäki has decided to leave the company after an admirable 34 years of service for Orion Pharma and 19 years on the Orion Executive Team. I take the opportunity here to thank her for all her commitment and work during those years. Her legacy will remain. I think she has worked with all the business divisions and left her mark on all the businesses that we do, and we will continue her precious work. And here you can see our upcoming events. And I thank you for your attention. I believe it is time for questions and discussions.
Thank you, Liisa, for the presentation. As I said, now it is time for Q&A. As I said, we will start with the conference call lines. But also, remember that you have the opportunity to type in your questions through the webcast chat. But at this point, I would like to hand over to the conference call. Operator. Please go ahead with the questions.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six. Six on your telephone keypad. The next question comes from Alex Moore from Bank of America. Please go ahead.
Hi. Thanks for taking my questions. I have three questions, all regarding Nubeqa. I'm afraid so. The first question is regarding Nubeqa royalties. Following up on your comments at Q2, is it still reasonable to assume royalty growth in the fourth quarter should be roughly in line with Nubeqa in-market sales, given you've already reached the maximum royalty tier and there is consensus that this assumption of roughly 10% sequential growth for in-market sales is broadly consistent with the assumptions underpinning your updated guidance?
Yes, maybe I will take the royalty question.
Yes. I mean, the maximum royalty percentage has been reached already. As Liisa Hurme said in Q2. So from that perspective, naturally, the royalties then would be directly proportional to the market sales that Bayer would then report to us. And then, of course, what the growth is in Q4. We will then see, but you can see our guidance and outlook and estimate from there as well. What might be the potential range for Nubeqa?
Okay, great. So, second question, just on tablet sales; I think tablet sales declined about 10% sequentially in the quarter. Can you confirm whether this was mainly due to the maintenance break. And I think your commentary at Q2 implied you typically back up to full production in the fourth quarter. So, should we expect year-on-year growth for tablet sales in Q4 to be roughly similar to what we saw in the second quarter?
Yes, there usually is a bit of a fluctuation due to the maintenance break, but I think the change now between the Q2 and Q3 is just a normal variation of how we ship out the tablets from Fermion to Orion, and then from Orion Pharma to Bayer. So I don't think there is anything specific, and there might still be variation between the quarters. I don't know, is there something you want to add?
No. It's like you said that there will always be fluctuations depending on the shipments. And those can be quite big as we ship in large batches. So, it's hard to say if the next quarter will be up or down. So I think the general trend, if you look at the year, is upward and in the right direction, of course.
Okay, great. So, this is my last question, which is more on your long-term ambition for Nubeqa. So, just on the recent positive interim readout for DASL-HiCaP, I think you've previously said that your greater than €1 billion guidance for Nubeqa sales by the end of the decade includes potential early line expansion. Can you give any color on what sort of risk adjustment was used relating to the DASL-HiCaP opportunity in that guidance? Given you appear to reach that milestone for Nubeqa sales either this year or next, based on current indications alone and the quite large potential addressable population for DASL-HiCaP, does this not imply meaningful upside to the lower end of that target? Therefore, what specifically needs to occur before you can de-risk and potentially quantify the upside to your long-term Nubeqa revenue guide?
Well, I may start and then continue on our guidance; as our partner has said, and as we have stated many times, we need positive results from these early-line studies to fulfill the full potential that Bayer has projected for Nubeqa. And we all know that they have said that this will be the biggest product that they have ever had, which means that it will be around €5 billion. So these DASL-HiCaP positive interim results, let's remember, are already included in those numbers. I think the question regarding if we are able to then update our guidance is a bit of a separate one. And it's not. I don't think it is time for that now. I think that might come later, but right now we follow that guidance.
Thank you very much.
The next question comes from Anzi Rossi from SEB. Please go ahead.
Yes. Hi, Juhani. Thank you for the presentation. First question on your expenses. Of course, we know that the research and development and also sales and marketing expenses were clearly higher in Q4 last year compared to the other three quarters of that year. So do you think that these expenses will actually increase or decrease in Q4 this year compared to the fourth quarter of last year?
Yeah. We are not giving guidance specifically on Q4 expenses and how those will pan out. So we still maintain our full-year guidance. But I think overall, last year had certain dynamics when it came, especially to the R&D expenses that did jump at that point in time. But I still would encourage you to look at the full year and, from that, deduce the full-year potential expenses that we will have. But I mean, nothing material comes to mind in terms of Q4 being very different from the others this year. I mean, although sometimes in Q4, there are questions that. How do we book R&D expenses? Depending on how the projects are actually progressing. And that will then have a certain variation, which of course also is partly reflected in our outlook, although in a much minor component than the potential Nubeqa scenarios.
Okay. Understood. And then, about Nubeqa tariffs. So can you give us an update on your estimates? And also, maybe as you mentioned, this contract manufacturing in the U.S. Can you mitigate this impact with this kind of agreement in the future?
Yes. On tariffs, there is really no change from where we were last quarter. I mean, basically, if you look at what we know, those tariffs should be operational and applied from the beginning of October onwards. So in a way, we do estimate that there is some tariff impact in Q4, at least according to what we know. In the end, we will only see that once we actually see when those are booked at the customs and we see how those are treated. So yes, we do assume some tariffs, but they are quite minor for Q4. And we will basically have to wait and see how those really are calculated in the end. And for the second part of the question regarding API manufacturing in the U.S., naturally that could have an impact on tariffs, but that is also something to be seen. So, hopefully, it will have an impact on that. But it also impacts our overall global supply of darolutamide.
And I think that is the most important thing that we now have. Again, we have another facility where we manufacture darolutamide API.
Okay. Got it. And the final question from me. You mentioned that there are some new products entering the clinical phase in the coming months. So could you comment on what kind of molecules these are or provide any additional color on them? Thanks.
All right. I guess you are referring to the upcoming period. I already mentioned ODM-216, the bispecific antibody. But yes, I think I've been bullish enough already early this year to say that we will bring at least one biologic into our clinical pipeline. But I might be even more bullish here and say that there might be another new phase one program even during this year.
Okay. Understood? Thank you so much.
The next question comes from Sami Sarikamis from Danske Bank Markets. Please go ahead.
Hi. I have three questions. We will start with Nubeqa. You announced today that you are going to be using contract manufacturers going forward. Can you elaborate on your thinking regarding what has changed? Is this related to potentially higher peak sales, risk management, or US tariffs? And how do you think this will impact Nubeqa gross margins in the long run?
Good question. Definitely. When we see that the volumes have been growing much faster and higher than originally estimated, it is important to manage your supplier risks. And that means that you need to have several site suppliers supplying the key ingredients like darolutamide API. And now we have two. We have one in Hong Kong, one in Germany, and then one will be in the United States. It is really to secure the volumes and manage our risks.
Okay. And what about the impact on Nubeqa gross margins? When will some of that capacity be taken into use?
I don't think I can comment on that.
Yes, of course. I mean, if you look at it, we will most likely be manufacturing the bulk of the API at the Hong Kong site, where we have been doing that for years. And of course, we are efficient; that I can say. So there will be some additional gross margin impact. Typically, when you build resilience, there is, of course, some price to that. But that resilience is worth paying for, because now you have more flexibility in how you use the sites and what volumes you need at any point in time; in the end, the impact will be marginal.
Exactly.
Okay. Then my second question would be on operating expenses. If we look at this here, R&D expenses have grown 20% since the marketing by roughly 10%. You are planning to become a more global company. So, what kind of growth rate in operating expenses are you thinking? Is it still going to be below top-line growth? Or could it be that, in the coming years, there will be margin erosion from your investments into the Orion platform?
Yes, maybe I can answer that. So that really depends on how our products move forward in the clinics and what the success rate is. So we are investing in R&D. We know that our pipeline is getting better and we should continue that. So that means also that the R&D spend as a percentage of revenue might in some years grow faster than the top line. Of course, our top line has been growing fast enough that even as we have been growing R&D by 20%, the top line has been slightly above that. So it can be lower, it can be higher, but it really will depend on the clinical pipeline and the sales and marketing, as well as the timing of the products we have coming into the market? There are some investments you need to do before the sales happen, especially on the innovative side. So then you need to invest before you see the sales. And then you could have, at least in the short term, an increase in sales and marketing expenses faster than the sales for that specific product or business division. But over time, that should catch up again. So there could be fluctuations. But there is nothing systematic that we can point out at this point.
Okay. And then my final question would be on the updated guidance. The range is still pretty wide going into the last quarter of the year. So can you elaborate a bit on the reservations and uncertainties you still have for the rest of the year?
Yeah. Yes, that is quite clear that the biggest reason for a wide range still is Nubeqa. As it is Q4, we have the maximum royalty rate and we have a fast-growing product. And Q4 is thereby estimated to be our best quarter also for Nubeqa. And there's a fairly broad range where this year could end up. I think the rest of the businesses have much smaller ranges and are, in a way, easier to predict, but Nubeqa, with such a growth curve and momentum, naturally gives quite a broad range still at this point, even though we narrowed it down a little bit in this latest outlook.
Okay, thanks. I don't have any further questions.
The next question comes from Sean Homma from Jefferies. Please go ahead.
Hi there. Thank you for taking my questions. I have three, if I may. So firstly, just on Nubeqa royalties for this quarter. At first glance, they seem a little bit soft versus consensus expectations. Is there any particular reason for this, such as potentially a correction for your estimate for the last month of the last quarter? That is my first question. I will ask the other two later. Thanks.
Yeah. Of course, there is always a matter of estimation when we go into a quarter, as we have discussed quite often, both on the first incoming month and the last month; that can be one source of why, later, when you compare to any Bayer number, you can see a discrepancy. But of course, at this point in time, I am not commenting on any expectations regarding that number, but as I said, it is an estimate. The last month.
Understood. Thank you. And then my next question is, how do you anticipate Nubeqa's underlying market trajectory to develop through this quarter and then also into 2027, particularly with enzalutamide generics expected to come online potentially end of next year into 2028?
Well, I don't think we are in a position to give any guidance regarding Nubeqa growth rate for 2027 or even the fourth quarter. I think that's a good question to ask Bayer. I think so. So what we are always referring to is the fact that Bayer has said this will be the biggest product they have ever had. To reach that, we will need to be successful in all the studies that are ongoing now. And fortunately, we have seen good interim results on DASL-HiCaP. So I think it's all on the positive side, but I wouldn't go and predict any definite numbers.
No, I think it is easy to say that the general direction is that we have quite far to go still to reach that peak year. And from that perspective, one could say that the general momentum of growth will continue for a few years to come.
Thank you so much. And then just finally, for me, as you mentioned, DASL-HiCaP, how are you thinking about your option for that indication? I mean, in terms of an exercise timeline, just because of course, the data are pretty encouraging at ESMO over the weekend.
Indeed, the data was very encouraging. And let's remember it is an IIS study. So it is an investigator-initiated study. And we have an opt-in possibility. We are now planning and have an understanding with Bayer that we would use that opt-in if and when they submit a marketing approval application. But that will, of course, be somewhere in the future.
Thank you so much.
As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Matti Korhola from OP Corporate Bank. Please go ahead.
Hello and good afternoon on my behalf as well. I still would like to ask about your guidance. So in your guidance, you are expecting a strong Q4 result. The strength should come from gross margins as the sales guidance did not increase, or increased less than the EBIT guidance. So where is the strength in gross margins coming in Q4 compared to Q3? As you should already be at the highest royalty rate. Really?
Yeah. I think the only quick answer I can provide is that, of course, the share of Nubeqa royalties will be larger than before in Q4. And that strengthens the overall gross margin and gross profit for the whole company.
But there are no production costs lower in Q4 compared to Q3 because of the name.
Nothing. Nothing. Nothing like that. No.
Okay. Okay. Then I think the things that still need to be cleared, but the value that, for example, the US Customs is using is quite close to what Bayer is referring to. As I said, I'm just thinking whether the duty will be really calculated from some sort of sales price, or is there any kind of indication, as it has been almost one month since they have been collected?
No, at the moment there is not. There is a range of scenarios for how this could be calculated. We will see when that is actually done. So I think I have nothing new that we can report on tariffs at this point in time.
Okay. And then one final question. So, regarding this Nubeqa contract manufacturing. So is it the case that you are producing the API there, but the tablet or the formulation is still done in Espoo, or how is the whole chain changing or going forward?
I assume you are talking about Nubeqa. Yes, we are manufacturing the API. Yes, in Hong Kong and in the other sites that we already discussed. And then the tablets are manufactured at our manufacturing site.
Okay. So the final products are still being shipped from our facilities.
Yes.
Yes. Thank you.
There are no more questions at this time.
All right. Thank you. Operator. Then we turn to the webcast questions. We have a few of them. Let's start with one coming from Iris Hummast from Carnegie. So what is your current plan for ODM-212? Do you plan to develop it yourself or are you looking for a partner before the phase three study?
Right now, we are planning to carry out the studies by ourselves. We are in phase two, and those studies we are carrying out by ourselves. As it seems now, both indications, both the AR and the mesothelioma, are such that we can conduct those phase three studies by ourselves.
Thank you, Liisa. Then moving on, one question regarding animal health. So could you please provide further details on the animal health performance, specifically regarding the timing of shipments and any other contributing factors that may exist? Do you expect better growth from this division for the remainder of 2026? And how about going into 2027?
Yes, maybe I will start there. So. So, of course for this year, I think there are some geopolitical headwinds in that business, especially in the livestock business, which have been delaying shipments, especially to the Middle East and Africa. We all know that can take some time. That is one reason why we are a bit behind in net sales. But other than that, if those shipments go through and other things that are planned for the full year, I think this year still has the potential to be at a good level. And for next year, we will have to see when we provide the guidance for the outlook.
Yes, exactly.
It may be. In other words, the sales would materialize. The demand is there, and there would be sales. But there has really been some struggle on the Middle East and African front.
Great. Then a follow-up from Iris regarding DASL-HiCaP. Can you comment on Bayer's regulatory plans following the DASL-HiCaP interim readout? And do you expect FDA discussions to begin soon?
What we know from Bayer is that they are planning to have discussions at some point with the FDA, and we will then see where that leads regarding the registration and marketing approval application, but we do not know more than that. But with such encouraging results, of course, we all hope that everything will go well.
Then another question. This comes from Becca. Given that Nubeqa continues to drive such a massive share of revenue and operating profit, how are you managing the concentration risk? Specifically, how is the current cash flow from Nubeqa being deployed into the R&D pipeline to ensure a sustainable growth engine before we eventually approach the patent cliff?
That is a good question. I think that is one of the major activities in our strategy currently, as we are developing new molecules. We are increasing our R&D budget year on year, pushing new products into Phase I, Phase II, and eventually to Phase III, while also using that cash to build new capabilities in R&D and on different commercial fronts. And that is why we own R&D and own capabilities. But of course, we are also constantly looking for new products and assets to be in-licensed or acquired. So there are a lot of activities ongoing to prepare for the 2030s and 2040s.
Thanks, Liisa. Then a couple of questions also from Pekka relating to the use of AI. So there are a couple of questions, but maybe I can sum them up in one question. So how is Orion currently leveraging artificial intelligence, quantum computing, and machine learning in R&D. In which areas are you deploying those?
I will start with R&D, especially in early-stage research where we handle huge amounts of information; we go through not millions, but sometimes billions of molecular structures when we are trying to find a solution for a certain disease or a specific pathway that will have an effect on a cancer tumor. Other diseases like Parkinson's disease. And then the quantum capacity, of course, solves something, but also we use different artificial intelligence tools that we have found across the world. So we work with several companies in the US, in the UK, and here in Finland to find new ways and technologies to speed up that phase in the development. We have already seen that. We have been able to halve the time in the discovery and research. So there is a lot going on and it's by no means a new thing for us, but we've been doing that almost for ten years now. We already see good results. And then, of course, when you get to the clinical studies, you can also use artificial intelligence in many ways. When you are determining or defining your clinical patient population. So you can use these kinds of digital twins to test your molecule and try to define what would be the best patient population for your studies. And between each clinical stage, from phase one to phase two and phase three. Of course, AI brings tools to speed up the transition from one stage to another.
Thank you. And currently, the final question from the chat is, how should we think about Nubeqa® exclusivity beyond 2033, particularly in light of the later expiring US patents?
Well, the basic patent that expires in 2033 is the one that will hold, I think. And that is the one on which generally all the pharmaceutical companies rely. And in this industry, we rely on it.
So, basically, there are others. But we rely on the 2033 date. So it's too early to speculate on any results from other patents. We will have to wait and see.
Yes.
All right. Thank you. Now, we have exhausted all the questions both online and from the conference call line. So it is time to wrap up, and maybe the final words from Liisa.
Thank you for your attendance. And it was our pleasure to report the strong Q3 results. And we are really looking forward to this ongoing quarter to finalize this good year. Thank you.



















